Iofina Plc a ‘Buy’ on Robust Pricing and Further Customer Demand, Alex Brooks, Canacccord 7 February 2025
Norcros plc offers “considerable upside” as acquisitions strengthen growth, highlights fund manager (LON:NXR) 9 February 2026
Victorian Plumbing Group set for strong growth as scale and efficiency improve, hails fund manager 9 February 2026
Yü Group backed for strong upside as Premier Miton highlights low valuation and market share gains 9 February 2026
Gervais Williams backs Ithaca Energy for sustained returns and exceptional dividend potential (LON:ITH) 9 February 2026
Vistry Group PLC (VTY.L) Stock Analysis: Navigating a Challenging Residential Market with Strategic Insights 9 February 2026
Standard Chartered PLC (STAN.L) Stock Analysis: Evaluating Growth Amidst Volatility and a 9.72% ROE 9 February 2026
Unilever PLC (ULVR.L) Stock Analysis: Navigating the Consumer Goods Giant’s Market Position and Analyst Ratings 9 February 2026
Weir Group PLC (WEIR.L): Analyst Ratings Highlight Strong Buy Consensus Amidst Impressive Stock Performance 9 February 2026
Reckitt Benckiser Group PLC (RKT.L) Stock Analysis: Navigating a 6.29% Upside Amid Strong ROE 9 February 2026
Iofina Plc a ‘Buy’ on Robust Pricing and Further Customer Demand, Alex Brooks, Canacccord 7 February 2025
Norcros plc offers “considerable upside” as acquisitions strengthen growth, highlights fund manager (LON:NXR) 9 February 2026
Victorian Plumbing Group set for strong growth as scale and efficiency improve, hails fund manager 9 February 2026
Yü Group backed for strong upside as Premier Miton highlights low valuation and market share gains 9 February 2026
Gervais Williams backs Ithaca Energy for sustained returns and exceptional dividend potential (LON:ITH) 9 February 2026
Vistry Group PLC (VTY.L) Stock Analysis: Navigating a Challenging Residential Market with Strategic Insights 9 February 2026
Standard Chartered PLC (STAN.L) Stock Analysis: Evaluating Growth Amidst Volatility and a 9.72% ROE 9 February 2026
Unilever PLC (ULVR.L) Stock Analysis: Navigating the Consumer Goods Giant’s Market Position and Analyst Ratings 9 February 2026
Weir Group PLC (WEIR.L): Analyst Ratings Highlight Strong Buy Consensus Amidst Impressive Stock Performance 9 February 2026
Reckitt Benckiser Group PLC (RKT.L) Stock Analysis: Navigating a 6.29% Upside Amid Strong ROE 9 February 2026
Immunome, Inc. (IMNM) Stock Analysis: A Promising Biotech Play with 53% Upside Potential 26 December 2025
iRadimed Corporation (IRMD) Stock Analysis: Riding High with Strong Revenue Growth and Analyst Confidence 26 December 2025
InMode Ltd. (INMD) Stock Analysis: Unveiling Growth Potential Amidst Market Challenges 26 December 2025
CeriBell, Inc. (CBLL) Stock Analysis: A Medical Device Innovator with 31% Revenue Growth and Strong Buy Ratings 26 December 2025
Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Star with 23.79% Potential Upside 26 December 2025
Evolus, Inc. (EOLS) Stock Analysis: Unveiling a 170% Upside Potential for Savvy Investors 26 December 2025
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Navigating a 117% Revenue Growth in Biotech 26 December 2025
Butterfly Network, Inc. (BFLY) Investor Outlook: Analyzing Growth Potential in the Medical Devices Sector 26 December 2025
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Unpacking a Potential 150% Upside in the Biotech Arena 26 December 2025
Vir Biotechnology, Inc. (VIR) Stock Analysis: Unveiling a Potential 181% Upside in the Biotechnology Sector 26 December 2025
Neuropace, Inc. (NPCE) Stock Analysis: Uncovering an 18.90% Upside Potential Amid Robust Revenue Growth 26 December 2025
KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Biotech with Nearly 96% Upside Potential 26 December 2025
Xencor, Inc. (XNCR) Stock Analysis: Strong Buy Ratings and 82.85% Potential Upside Capture Investor Attention 26 December 2025
CureVac N.V. (CVAC) Stock Analysis: A 25.92% Potential Upside Amid Market Volatility 26 December 2025
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a 213% Potential Upside in the Biotech Sector 26 December 2025
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Bold Vision in Biotechnology with 64.25% Potential Upside 26 December 2025
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a 491% Potential Upside in Biotechnology 26 December 2025
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Exploring a 78% Potential Upside in Biotech 26 December 2025
Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a 116% Potential Upside in the Healthcare Sector 26 December 2025
Akebia Therapeutics (AKBA): Investor Outlook with a Promising 217.65% Potential Upside 26 December 2025
Touchstone Exploration Strategic Moves to Dominate Onshore Gas Production in Trinidad (Video) 19 December 2024
Ferro-Alloy Resources CEO Nick Bridgen on Game-Changing Updates in Vanadium and Carbon Black (Video) 18 December 2024
Auctus Advisors Breaking Down Investment Opportunities in Helium’s Complex Landscape (Video) 13 December 2024
Iofina Plc a ‘Buy’ on Robust Pricing and Further Customer Demand, Alex Brooks, Canacccord 7 February 2025
Norcros plc offers “considerable upside” as acquisitions strengthen growth, highlights fund manager (LON:NXR) 9 February 2026
Victorian Plumbing Group set for strong growth as scale and efficiency improve, hails fund manager 9 February 2026
Yü Group backed for strong upside as Premier Miton highlights low valuation and market share gains 9 February 2026
Gervais Williams backs Ithaca Energy for sustained returns and exceptional dividend potential (LON:ITH) 9 February 2026
Vistry Group PLC (VTY.L) Stock Analysis: Navigating a Challenging Residential Market with Strategic Insights 9 February 2026
Standard Chartered PLC (STAN.L) Stock Analysis: Evaluating Growth Amidst Volatility and a 9.72% ROE 9 February 2026
Unilever PLC (ULVR.L) Stock Analysis: Navigating the Consumer Goods Giant’s Market Position and Analyst Ratings 9 February 2026
Weir Group PLC (WEIR.L): Analyst Ratings Highlight Strong Buy Consensus Amidst Impressive Stock Performance 9 February 2026
Reckitt Benckiser Group PLC (RKT.L) Stock Analysis: Navigating a 6.29% Upside Amid Strong ROE 9 February 2026
